201. A drug-drug interaction study of ibrutinib with moderate/strong CYP3A inhibitors in patients with B-cell malignancies.
- Author
-
de Jong J, Hellemans P, De Wilde S, Patricia D, Masterson T, Manikhas G, Myasnikov A, Osmanov D, Córdoba R, Panizo C, de Zwart L, Snoeys J, Chauhan V, Jiao J, Sukbuntherng J, and Ouellet D
- Subjects
- Adenine analogs & derivatives, Administration, Oral, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Cytochrome P-450 CYP2C19 genetics, Cytochrome P-450 CYP3A genetics, Cytochrome P-450 CYP3A Inhibitors therapeutic use, Diarrhea chemically induced, Diarrhea epidemiology, Dose-Response Relationship, Drug, Drug Administration Schedule, Drug Interactions, Erythromycin pharmacology, Erythromycin therapeutic use, Female, Hematologic Neoplasms genetics, Hematologic Neoplasms pathology, Humans, Male, Middle Aged, Neutropenia chemically induced, Neutropenia epidemiology, Piperidines, Polymorphism, Single Nucleotide, Pyrazoles therapeutic use, Pyrimidines therapeutic use, Voriconazole pharmacology, Voriconazole therapeutic use, Antineoplastic Combined Chemotherapy Protocols pharmacology, B-Lymphocytes pathology, Cytochrome P-450 CYP3A Inhibitors pharmacology, Hematologic Neoplasms drug therapy, Pyrazoles pharmacology, Pyrimidines pharmacology
- Abstract
This was an open-label, multicenter, phase-1 study to evaluate the drug interaction between steady-state ibrutinib and moderate (erythromycin) and strong (voriconazole) CYP3A inhibitors in patients with B-cell malignancies and to confirm dosing recommendations. During cycle 1, patients received oral ibrutinib 560 mg qd alone (Days 1-4 and 14-18), and ibrutinib 140 mg (Days 5-13; 19-27) plus erythromycin 500 mg tid (Days 5-11) and voriconazole 200 mg bid (Days 19-25). Twenty-six patients (median [range] age: 64.5 [50-88] years) were enrolled. Geometric mean ratio (90% confidence intervals) after co-administration of ibrutinib 140 mg with erythromycin and voriconazole was 74.7 (53.97-103.51) and 143.3 (107.77-190.42), respectively, versus ibrutinib 560 mg alone. The most common (≥20%) adverse events were diarrhea (27%) and neutropenia (23%). The results demonstrate that ibrutinib 140 mg with voriconazole or erythromycin provides exposure within the clinical range for patients with B-cell malignancies.
- Published
- 2018
- Full Text
- View/download PDF